MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
6.96
+0.08 (1.09%)
Nov 21, 2024, 1:24 PM EST - Market open
MannKind Employees
As of December 31, 2023, MannKind had 414 total employees, including 411 full-time and 3 part-time employees. The number of employees increased by 19 or 4.81% compared to the previous year.
Employees
414
Change (1Y)
19
Growth (1Y)
4.81%
Revenue / Employee
$645,411
Profits / Employee
$52,094
Market Cap
1.92B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
National HealthCare | 13,123 |
Patterson Companies | 7,600 |
Evotec SE | 5,061 |
Azenta | 3,500 |
Tandem Diabetes Care | 2,400 |
NeoGenomics | 2,100 |
GeneDx Holdings | 1,000 |
Supernus Pharmaceuticals | 652 |
MNKD News
- 13 days ago - MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 13 days ago - MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 15 days ago - MannKind to Present at 2024 UBS Healthcare Conference - GlobeNewsWire
- 17 days ago - MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases - GlobeNewsWire
- 20 days ago - MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024 - GlobeNewsWire
- 21 days ago - First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease - GlobeNewsWire
- 7 weeks ago - MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion - Seeking Alpha
- 7 weeks ago - More Adults With Type 1 Diabetes Achieved A1C Goal ( - GlobeNewsWire